200 related articles for article (PubMed ID: 36068210)
21. Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.
Faraj P; Hermansen A; Molden E; Hole K
Ther Drug Monit; 2022 Dec; 44(6):720-728. PubMed ID: 36372933
[TBL] [Abstract][Full Text] [Related]
22. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
23. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.
Hodgson K; Tansey K; Dernovsek MZ; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Smith R; Craig IW; Farmer AE; Aitchison KJ; Belsey S; Davis OS; Uher R; McGuffin P
J Psychopharmacol; 2014 Feb; 28(2):133-41. PubMed ID: 24257813
[TBL] [Abstract][Full Text] [Related]
24. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
[No Abstract] [Full Text] [Related]
25. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
26. CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression.
Bernini de Brito R; Ghedini PC
Heliyon; 2020 May; 6(5):e04015. PubMed ID: 32509985
[TBL] [Abstract][Full Text] [Related]
27. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
[TBL] [Abstract][Full Text] [Related]
28. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
29. Exploring the role of drug-metabolising enzymes in antidepressant side effects.
Hodgson K; Tansey KE; Uher R; Dernovšek MZ; Mors O; Hauser J; Souery D; Maier W; Henigsberg N; Rietschel M; Placentino A; Craig IW; Aitchison KJ; Farmer AE; Dobson RJ; McGuffin P
Psychopharmacology (Berl); 2015 Jul; 232(14):2609-17. PubMed ID: 25761838
[TBL] [Abstract][Full Text] [Related]
30. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
31. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
32. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
Müller DJ; Kekin I; Kao AC; Brandl EJ
Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
34. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
Brandl EJ; Tiwari AK; Zhou X; Deluce J; Kennedy JL; Müller DJ; Richter MA
Pharmacogenomics J; 2014 Apr; 14(2):176-81. PubMed ID: 23545896
[TBL] [Abstract][Full Text] [Related]
36. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
37. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
38. Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.
He Q; Mei Y; Liu Y; Yuan Z; Zhang J; Yan H; Shen L; Zhang Y
J Clin Psychopharmacol; 2019; 39(2):117-123. PubMed ID: 30742590
[TBL] [Abstract][Full Text] [Related]
39. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
[TBL] [Abstract][Full Text] [Related]
40. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]